Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients

This is the authors' abstract. We don't add key points for this paper.

Cytomegalovirus (CMV) is a driver of negative outcomes after lung transplant (LTX) and primary prophylaxis (PPX) with valganciclovir (VGC) is standard-of-care. VGC is associated with myelosuppression, prompting interest in letermovir (LTV).